Bioxyne (ASX:BXNDA) FFO


ASX:BXNDA Bioxyne Ltd ASX:BXNDA
50 GF Score
Price A$0.95
GF Value A$0.69
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bioxyne FFO?

FFO (Funds from operations) only applies to REITs.

ASX:BXNDA
50GF Score
Bioxyne Ltd ASX:BXNDA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioxyne (ASX:BXNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Bioxyne stock appears to be overvalued. The current stock price of A$0.95 is trading 37.7% above its estimated GF Value™ of A$0.69. GuruFocus considers Bioxyne to be Significantly Overvalued.

Key valuation signals for ASX:BXNDA:

  • FFO:
  • GF Value™: A$0.69 vs. price of A$0.95 (37.7% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the ASX:BXNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioxyne Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
50GF Score

Get the complete analysis for ASX:BXNDA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.95
Price
A$0.69
GF Value